John Tesser

4.9k total citations · 2 hit papers
48 papers, 3.7k citations indexed

About

John Tesser is a scholar working on Rheumatology, Hematology and Immunology. According to data from OpenAlex, John Tesser has authored 48 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Rheumatology, 20 papers in Hematology and 11 papers in Immunology. Recurrent topics in John Tesser's work include Rheumatoid Arthritis Research and Therapies (30 papers), Autoimmune and Inflammatory Disorders Research (20 papers) and Systemic Lupus Erythematosus Research (10 papers). John Tesser is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (30 papers), Autoimmune and Inflammatory Disorders Research (20 papers) and Systemic Lupus Erythematosus Research (10 papers). John Tesser collaborates with scholars based in United States, Canada and United Kingdom. John Tesser's co-authors include Roy Fleischmann, Michael Schiff, Joan M. Bathon, Larry W. Moreland, Edward Keystone, Mark C. Genovese, Arthur L. Weaver, Joseph A. Markenson, Richard W. Martin and Mary Chester Wasko and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Annals of the Rheumatic Diseases.

In The Last Decade

John Tesser

48 papers receiving 3.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A Comparison of Etanercept and Methotrexate in Patients with Early Rheumatoid Arthritis

2000 1.4k citations Roy Fleischmann, John Tesser et al. New England Journal of Medicine profile →
Etanercept versus methotrexate in patients with early rheumatoid arthritis: Two‐year radiographic and clinical outcomes

2002 573 citations Mark C. Genovese, Roy Fleischmann et al. Arthritis & Rheumatism profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
John Tesser United States	21	2.7k	1.4k	864	560	346	48	3.7k
Rolf Rau Germany	23	2.4k 0.9×	963 0.7×	770 0.9×	394 0.7×	310 0.9×	39	3.3k
Pierre Geborek Sweden	33	2.5k 0.9×	889 0.7×	1.1k 1.3×	509 0.9×	454 1.3×	73	3.6k
Daniel Burge United States	14	2.6k 1.0×	1.5k 1.1×	1.6k 1.9×	344 0.6×	353 1.0×	23	3.9k
J. Nam United Kingdom	21	2.4k 0.9×	887 0.7×	723 0.8×	414 0.7×	262 0.8×	57	3.0k
John J. Cush United States	31	2.5k 0.9×	1.2k 0.9×	1.6k 1.8×	399 0.7×	262 0.8×	59	4.3k
Hideto Kameda Japan	38	2.6k 1.0×	1.2k 0.9×	1.2k 1.3×	631 1.1×	628 1.8×	196	4.3k
Barbara Finck United States	8	2.7k 1.0×	1.5k 1.1×	1.3k 1.6×	375 0.7×	309 0.9×	17	3.6k
Elliot Chartash United States	23	3.0k 1.1×	1.5k 1.1×	1.4k 1.6×	601 1.1×	474 1.4×	49	4.7k
Arnaud Constantin France	30	1.9k 0.7×	605 0.4×	829 1.0×	329 0.6×	304 0.9×	120	3.1k
Emilio Martín Mola Spain	14	2.5k 1.0×	1.2k 0.9×	792 0.9×	524 0.9×	356 1.0×	32	3.7k

Countries citing papers authored by John Tesser

Since Specialization

Citations

This map shows the geographic impact of John Tesser's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Tesser with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Tesser more than expected).

Fields of papers citing papers by John Tesser

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John Tesser. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Tesser. The network helps show where John Tesser may publish in the future.

Co-authorship network of co-authors of John Tesser

This figure shows the co-authorship network connecting the top 25 collaborators of John Tesser. A scholar is included among the top collaborators of John Tesser based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John Tesser. John Tesser is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Burmester, Gerd R, Filip Van den Bosch, John Tesser, et al.. (2024). Upadacitinib in Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs: Efficacy and Safety Through 5 Years (SELECT-NEXT). The Journal of Rheumatology. 51(7). 663–672. 3 indexed citations

Ritchlin, Christopher T., Philip J. Mease, Wolf‐Henning Boehncke, et al.. (2024). Durable control of psoriatic arthritis with guselkumab across domains and patient characteristics: post hoc analysis of a phase 3 study. Clinical Rheumatology. 43(8). 2551–2563. 1 indexed citations

Mease, Philip J., Alexis Ogdie, John Tesser, et al.. (2024). Improvements in Patient‐Reported Outcomes Through Six Months of Guselkumab Treatment in Patients With Active Psoriatic Arthritis: Real‐World Data From the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry. ACR Open Rheumatology. 6(5). 304–311. 1 indexed citations

Ritchlin, Christopher T., Philip J. Mease, Wolf‐Henning Boehncke, et al.. (2023). AB1104 STRINGENT DISEASE ACTIVITY CONTROL AT 2 YEARS ACROSS PSORIATIC ARTHRITIS DOMAINS IRRESPECTIVE OF BASELINE CHARACTERISTICS IN PATIENTS TREATED WITH GUSELKUMAB: POST-HOC ANALYSIS OF A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY. 1779–1780. 2 indexed citations

Mease, Philip J., Alexis Ogdie, John Tesser, et al.. (2023). Six-Month Persistence and Multi-domain Effectiveness of Guselkumab in Adults with Psoriatic Arthritis: Real-World Data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry. Rheumatology and Therapy. 10(6). 1479–1501. 9 indexed citations

Baker, Matthew, Sarah Kavanagh, Stanley Cohen, et al.. (2023). A Randomized, Double‐Blind, Sham‐Controlled, Clinical Trial of Auricular Vagus Nerve Stimulation for the Treatment of Active Rheumatoid Arthritis. Arthritis & Rheumatology. 75(12). 2107–2115. 14 indexed citations

Saag, Kenneth G., K. Obermeyer, Brian LaMoreaux, et al.. (2023). A Randomized, Double‐Blind, Placebo‐Controlled Multicenter Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients With Uncontrolled Gout Receiving Pegloticase: 12‐Month Findings. ACR Open Rheumatology. 5(8). 407–418. 13 indexed citations

Ritchlin, Christopher T., Philip J. Mease, Wolf‐Henning Boehncke, et al.. (2022). Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III, randomised, placebo-controlled studies. RMD Open. 8(1). e002195–e002195. 18 indexed citations

Tesser, John, Natalie J. Shiff, Soumya D. Chakravarty, et al.. (2022). Improvement in disease activity among patients with rheumatoid arthritis who switched from intravenous infliximab to intravenous golimumab in the ACR RISE registry. Clinical Rheumatology. 41(8). 2319–2327. 2 indexed citations

10.

Saag, Kenneth G., Stephen Ong, K. Obermeyer, et al.. (2022). A Randomized, Placebo‐Controlled Study of Methotrexate to Increase Response Rates in Patients with Uncontrolled Gout Receiving Pegloticase: Primary Efficacy and Safety Findings. Arthritis & Rheumatology. 75(2). 293–304. 35 indexed citations

11.

Tesser, John, H. Mark Kenney, Paul M. Peloso, et al.. (2022). A multicentre, efficacy and safety study of methotrexate to increase response rates in patients with uncontrolled gout receiving pegloticase (MIRROR): 12-month efficacy, safety, immunogenicity, and pharmacokinetic findings during long-term extension of an open-label study. Arthritis Research & Therapy. 24(1). 208–208. 9 indexed citations

12.

Schiff, Michael, Johannes von Kempis, Ronald Goldblum, John Tesser, & Ruediger B. Müeller. (2014). Rheumatoid arthritis secondary non-responders to TNF can attain an efficacious and safe response by switching to certolizumab pegol: a phase IV, randomised, multicentre, double-blind, 12-week study, followed by a 12-week open-label phase. Annals of the Rheumatic Diseases. 73(12). 2174–2177. 37 indexed citations

13.

Schnitzer, Thomas J., John Tesser, Kimberly Cooper, & Roy D. Altman. (2008). A 4-week randomized study of acetaminophen extended-release vs rofecoxib in knee osteoarthritis. Osteoarthritis and Cartilage. 17(1). 1–7. 8 indexed citations

14.

Schiff, Michael, John Tesser, Roy Fleischmann, et al.. (2004). The safety of anakinra in high‐risk patients with active rheumatoid arthritis: Six‐month observations of patients with comorbid conditions. Arthritis & Rheumatism. 50(6). 1752–1760. 66 indexed citations

15.

Tesser, John, Roy Fleischmann, Robin K. Dore, et al.. (2004). Concomitant medication use in a large, international, multicenter, placebo controlled trial of anakinra, a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis.. PubMed. 31(4). 649–54. 29 indexed citations

16.

Moreland, Larry W., Kevin R. King, Michael Weisman, et al.. (2001). Results of a phase-I/II randomized, masked, placebo-controlled trial of recombinant human interleukin-11 (rhIL-11) in the treatment of subjects with active rheumatoid arthritis. Arthritis Research & Therapy. 3(4). 247–52. 41 indexed citations

17.

Chen, Z., Michael Maricic, P. J. Lund, John Tesser, & Oscar Gluck. (1998). How the New Hologic Hip Normal Reference Values Affect the Densitometric Diagnosis of Osteoporosis. Osteoporosis International. 8(5). 423–427. 30 indexed citations

18.

Tenenbaum, Scott A., Janet C. Rice, Luis R. Espinoza, et al.. (1997). Use of antipolymer antibody assay in recipients of silicone breast implants. The Lancet. 349(9050). 449–454. 39 indexed citations

19.

Stein, C. Michael, Theodore Pincus, David E. Yocum, et al.. (1997). Combination treatment of severe rheumatoid arthritis with cyclosporine and methotrexate for forty‐eight weeks. An open‐label extension study. Arthritis & Rheumatism. 40(10). 1843–1851. 65 indexed citations

20.

Tugwell, Peter, Theodore Pincus, David E. Yocum, et al.. (1995). Combination Therapy with Cyclosporine and Methotrexate in Severe Rheumatoid Arthritis. New England Journal of Medicine. 333(3). 137–142. 375 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact